Company:  SIGA TECHNOLOGIES INC (SIGA)
Form Type:  10-Q
Filing Date:  8/5/2013 
CIK:  0001010086 
Address:  660 MADISON AVENUE
SUITE 1700
 
City, State, Zip:  NEW YORK, New York 10065 
Telephone:  212-672-9100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.64  
Change: 
0.05 (1.93%)  
Trade Time: 
Jul 22  
Market Cap: 
$140.81M
Description of Business
Since we were incorporated in Delaware on December 28, 1995, SIGA has pursued the research, development and commercialization of novel products for the prevention and treatment of serious infectious diseases, including products for use in defense against biological warfare agents such as smallpox and Arenaviruses. Our lead product, ST-246�, is an orally administered antiviral drug that targets orthopox viruses. In December 2006 the FDA granted Orphan Drug designation to ST-246� for the prevention and treatment of smallpox. In May 2009, we submitted a response to a Request for Proposal (�RFP�) issued by BARDA with respect to the purchase of 1.7 million courses of a smallpox antiviral (the �BARDA Smallpox RFP�), and, in June 2009, BARDA informed us that our response to the BARDA Smallpox RFP was deemed technically acceptable and in the competitive range. There can be no assurance that SIGA or any other company will receive an award pursuant to this RFP.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1 - Condensed Consolidated Financial Statements
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II - OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sale of Equity Securities and Use of ...
      Item 3. Defaults upon Senior Securities
      Item 4. Mine Safety Disclosures
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURES
  EXHIBIT 31.1
    Certification by Chief Executive Officer Pursuant to
  EXHIBIT 31.2
    Certification by Chief Financial Officer Pursuant to
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO
  EXHIBIT 32.2
    CERTIFICATION PURSUANT TO
BROKERAGE PARTNERS